



RAVIMIAMET

Katrin Moeschlin
Merck Sharp & Dohme LLC
Levelingstrasse 4a
81673 München
GERMANY

12.02.2024 nr RKU-4/10

DECISION

to grant authorisation for clinical trial on the basis of Regulation (EU) No 536/2014 of the European Parliament and of the council

State Agency of Medicines has received the application from sponsor Merck Sharp & Dohme LLC on 20.12.2023 to conduct a clinical trial under the conditions stipulated in Regulation (EU) No 536/2014 art 5 (1) and § 99¹ (1) of Estonian Medicinal Products Act (MPA).

Based on art 8 of Regulation (EU) No 536/2014, considering the aspects covered by Part I and Part II of the assessment report, on the basis of § 99⁶ section 1 p 1 and (3) of Medicinal Product Act

State Agency of Medicines has decided to give the approval to conduct the clinical study protocol no MK-2140-006 under the following conditions:

protocol no: MK-2140-006 (Version 06, dated September 22, 2023)

full title of the trial: A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants with Aggressive and Indolent B-cell Malignancies (waveLINE-006).

sponsor of the trial: Merck Sharp & Dohme LLC

number of subjects in Estonia: 5

principal investigators and study locations:

- Dr Mariken Ross, North Estonia Medical Centre Foundation, J. Sütiste tee 19, 13419 Tallinn, Estonia

The addressee may file a challenge with State Agency of Medicines within 30 days as of the day when the addressee became or should have become aware of the decision as prescribed in Code of Administrative Procedure § 71(1). If the addressee wishes to have the decision to annulled by the administrative court, he or she may submit a complaint to the Tartu Administrative Court as prescribed in § 7(1) and § 46(1) of the Code of Administrative Court Procedure within 30 days after the date on which the decision was notified to the applicant.

(digitally signed)

Katrin Kiisk
Director General